A detailed history of Baker Ellis Asset Management LLC transactions in Cardiff Oncology, Inc. stock. As of the latest transaction made, Baker Ellis Asset Management LLC holds 20,000 shares of CRDF stock, worth $50,199. This represents 0.01% of its overall portfolio holdings.

Number of Shares
20,000
Holding current value
$50,199
% of portfolio
0.01%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 15, 2024

BUY
$2.05 - $2.77 $41,000 - $55,400
20,000 New
20,000 $53,000

Others Institutions Holding CRDF

About Cardiff Oncology, Inc.


  • Ticker CRDF
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,334,900
  • Market Cap $109M
  • Description
  • Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...
More about CRDF
Track This Portfolio

Track Baker Ellis Asset Management LLC Portfolio

Follow Baker Ellis Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Baker Ellis Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Baker Ellis Asset Management LLC with notifications on news.